We are starting to see more drug delivery systems moving to an “inhaled” version and here’s one more example.  The drug is non-narcotic and should be free of the imagenormal side effects normally associated with that drug group.  In addition we are seeing new devices that contain drugs and some are wireless and can send data base to show compliance with data figure and a full audit trail.  Below are a couple links to some examples. 

Sensohaler Device To Help Drive Compliance With Inhaled Medications – Smart Medical Devices

The VenaHub Medical Device Hub Wirelessly Reports Health Data Compliance and the Blue Tooth Inhaler

Another company has a clinical trial in place to use inhalers to give relief for migraines too.

OptiNose’s Sumatriptan Product – Clinical Trials Show Favorable Results for (Sniffing or Snorting) Away a Migraine Headache

In communicating with the folks over at Cambridge Consultants, we had this conversation over a year ago with their experts telling us about how technology is going to affect how new drugs are created and delivered.  We have 2 different angles working here, one being a safer drug and delivery system and the other side of the coin is the folks that like to collect data and report on our compliance.  The second item here is a bit gray on where and how and who gets to see that information.

The Future of Drug Delivery Lies with Technology – Panel of Experts From Cambridge Consultants

Stay tuned as I try to keep everyone updated on how the drug delivery and data collected work together. The eventual process here is to gather all of this imageinformation and have it present in an PHR and of course an EHR.  What we don’t want is risk management using algorithms to let’s say deny a claim with substantiating a missed dose and today I don’t put anything like that past risk management in their ultimate quests for profit.  BD  

 From the website:

“Mild, transient nasal discomfort was the most frequently reported side-effect of SPRIX use. SPRIX is contraindicated in patients with known hypersensitivity or a history of allergic reactions to aspirin, ketorolac, other NSAIDs or EDTA; in patients at risk for GI bleeding; prior to major surgery or during the perioperative period in CABG surgery, in patients with advanced renal disease or volume depletion, patients with certain bleeding risk and during labor and delivery. SPRIX should not be used concurrently with probenecid or pentoxifylline. Treat patients for the shortest duration possible, and do not exceed 5 days of therapy with SPRIX.”

MONDAY, May 17 (HealthDay News) -- Roxro Pharma's Sprix (ketorolac tromethamine) nasal spray has been approved by the U.S. Food and Drug Administration for the short-term treatment of moderate to moderately severe pain, the manufacturer said Monday in a news release.

The nasal spray contains the non-steroidal anti-inflammatory drug (NSAID) ketorolac. The non-narcotic medication minimizes the chances for abuse and eliminates side effects associated with narcotic pain relievers, the drug maker said.

Sprix Approved for Moderate-to-Severe Pain


Post a Comment

Google Analytics Alternative